Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (unaudited)

v2.4.0.6
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (unaudited) (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Revenues:    
License and collaborative fees $ 399 $ 1,014
Contract and other 8,796 8,844
Net product sales 258 7
Total revenues 9,453 9,865
Operating expenses:    
Research and development 16,590 15,771
Selling, general and administrative 4,124 4,679
Restructuring 17 3,777
Cost of sales 46 0
Total operating expenses 20,777 24,227
Loss from operations (11,324) (14,362)
Other income (expense):    
Interest expense (1,172) (1,042)
Other income (expense) 449 (664)
Revaluation of contingent warrant liabilities (12,840) (14,357)
Net loss (24,887) (30,425)
Basic and diluted net loss per common stock (in dollars per share) $ (0.3) $ (0.69)
Shares used in computing basic and diluted net loss per share of common stock (in shares) 82,595 44,353
Other comprehensive loss:    
Net loss (24,887) (30,425)
Net unrealized gains on available-for-sale securities 3 0
Comprehensive loss $ (24,884) $ (30,425)